SACCANI, Francesca
 Distribuzione geografica
Continente #
EU - Europa 1.240
NA - Nord America 988
AS - Asia 414
Continente sconosciuto - Info sul continente non disponibili 5
Totale 2.647
Nazione #
US - Stati Uniti d'America 974
CN - Cina 360
FI - Finlandia 326
IE - Irlanda 283
SE - Svezia 278
IT - Italia 100
AT - Austria 72
UA - Ucraina 71
DE - Germania 67
TR - Turchia 47
BE - Belgio 24
CA - Canada 14
FR - Francia 9
EU - Europa 5
IN - India 4
GB - Regno Unito 3
RU - Federazione Russa 2
CH - Svizzera 1
HU - Ungheria 1
IR - Iran 1
JP - Giappone 1
MD - Moldavia 1
NL - Olanda 1
RO - Romania 1
VN - Vietnam 1
Totale 2.647
Città #
Dublin 283
Chandler 277
Beijing 99
Jacksonville 99
Dearborn 96
Parma 81
Nanjing 65
Vienna 63
Ann Arbor 48
Izmir 44
Princeton 39
Brussels 24
Wilmington 24
Boardman 23
Nanchang 23
San Mateo 23
Kunming 20
Hebei 19
Jinan 17
Bremen 16
Des Moines 15
Helsinki 15
Ashburn 13
Hefei 13
Guangzhou 12
Shenyang 11
Toronto 10
Changsha 9
Tianjin 9
Zhengzhou 9
Jiaxing 8
Norwalk 8
Hangzhou 7
Chengdu 4
Fremont 4
Woodbridge 4
Augusta 3
Chongqing 3
Fuzhou 3
Grafing 3
Houston 3
Kocaeli 3
Mantova 3
Rockville 3
Taizhou 3
Wenzhou 3
Düsseldorf 2
Gainesville 2
Haikou 2
Lanzhou 2
Mestre 2
Montreal 2
Montréal 2
Redmond 2
Redwood City 2
Reggio Nell'emilia 2
Seattle 2
Xian 2
Alchevs'k 1
Bangalore 1
Baotou 1
Bologna 1
Borås 1
Budapest 1
Cardiff 1
Castel Goffredo 1
Chicago 1
Chisinau 1
Focsani 1
Frankfurt am Main 1
Goose Creek 1
Hanoi 1
Huizen 1
Jamaica Plain 1
Langfang 1
Leawood 1
Modena 1
Montegaldella 1
New Delhi 1
Ningbo 1
Old Bridge 1
Philadelphia 1
Sassuolo 1
Shaoxing 1
Spezzano Albanese 1
Taiyuan 1
Tehran 1
Tokyo 1
Zurich 1
Totale 1.619
Nome #
Effect of μ Opioid Receptor Activation On Intestinal Ischemia/Reperfusion Injury in Mice 99
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 99
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 93
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 92
Suppression of inflammatory events associated to intestinal ischemia-reperfusion by 5-HT1A blockade in mice 91
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 87
Histamine H4 receptor antagonism and mesenteric ischemia/reperfusion injury in mice 82
Accommodation and peristalsis are functional responses to chronic obstruction in rat hypertrophic ileum 81
Gastrointestinal symptoms and local oxidative stress in a model of Parkinson's Disease in rats 81
Daily assumption of fermented milk containing Bifidobacterium breve 246 B® promotes prophylactic effects against intestinal inflammation in mice 80
Dual role of endogenous serotonin in 2,4,6-Trinitrobenzene Sulfonic Acid-induced colitis 77
Intestinal chronic obstruction affects motor responsiveness of rat hypertrophic longitudinal and circular muscles 77
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 77
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 76
A promising imidazole-free histamine H3 receptor antagonist with good brain penetration and anticholinesterase activity. 76
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 75
Lung mesenchymal cells function as an inductive microenvironment for human lung cancer propagating cells† 72
Identification and tumorigenic role of Mesenchymal Stem Cells from human lung cancer 71
Role of 5-HT in intestinal ischemia-reperfusion: suppression of inflammatory events by 5-HT1A blockade in mice 70
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 70
Accommodation and peristalsis are functional responses to obstruction in rat hypertrophic ileum 69
Synthesis of new 5,6-dihydrobenzo[h]quinazoline 2,4-diamino substituted and antiplatelet/antiphlogistic activities evaluation. 69
In vitro and in vivo pharmacological analysis of imidazole-free histamine H3 receptor antagonists: promising results for a brain-penetrating H3 blocker with weak anticholinesterase activity. 68
Analgesic activity of new hybrid muscarinic agonists in mice 67
Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity. 65
5-HT1A receptors as target to protect the intestine in an experimental model of colitis 63
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 61
Activation of μ opioid receptors ameliorates mucosal injury induced by intestinal ischemia and reperfusion in mice 60
Dual-Acting Drugs: an in vitro Study of Nonimidazole Histamine H(3) Receptor Antagonists Combining Anticholinesterase Activity 60
Multi-target-directed ligands: new histamine H3 receptor antagonists with anticholinesterase activity 58
Radiological analysis of gastrointestinal dysmotility associated with central dopaminergic impairment in an animal model of parkinson's disease (PD) 56
Preventive effect of 5-HT1A receptor agonist Buspirone on mesenteric ischemia/reperfusion-induced inflammatory injuries in mice 56
Pharmacological modulation of 5HT1A receptors in mice mesenteric ischemia/reperfusion injury: protective effect of Buspirone and WAY100135 52
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 52
Protective role of μ opioid receptor activation in intestinal inflammation induced by mesenteric ischemia/reperfusion in mice. 49
T-DM1: a new therapeutic approach in HER-2 overexpressing NSCLC cell lines 43
Pharmacological characterization of a new non-himidazole histamine H3 antagonist 42
Differential Tumorigenic Properties of Mesenchymal Cells From Neoplastic and Non-Neoplastic Human Lung in NSCLC 40
Investigation into the μ opioid receptor role in an experimental model of mesenteric ischemia/reperfusion 34
Totale 2.690
Categoria #
all - tutte 6.534
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.534


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019117 0 0 0 0 19 8 4 3 11 7 56 9
2019/2020585 102 133 28 12 34 65 68 9 39 48 18 29
2020/2021153 1 19 7 1 20 2 20 0 36 14 33 0
2021/2022174 2 0 0 25 6 3 23 21 8 10 9 67
2022/20231.066 119 132 62 85 81 113 33 41 321 5 53 21
2023/202494 24 23 7 15 25 0 0 0 0 0 0 0
Totale 2.690